13-valent pneumococcal conjugate vaccine (PCV13)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for 13-valent pneumococcal conjugate vaccine (PCV13), covering 2016-01-27 to 2017-01-23. Get the full timeline:
Most recent: Clinical Trial Update: A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine [Phase 2]